Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy

Lupusoru, Gabriela Elena; Ailincăi, Ioana; Sorohan, Bogdan; Andronesi, Andreea; Achim, Camelia; Micu, Georgia; Caragheorgheopol, Andra; Manda, Dana; Lupuşoru, Mircea; Ismail, Gener

doi:10.1016/j.diabres.2021.109116

Cited by 9 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequent CKD stage was stage IV (40%), followed by stages III-B (20%), III-A (17.1%), II (14.3%), V (5.7%), and I (2.9%). In line with our study, Lupuș oru et al (19) concluded that CKD stage 4 was (36%) is the most frequent CKD stage, stage 5 was (24%), stage 3B was (18.6%), stage 2 was (8%), stage 3A was (6.7%), and stage 1 was (6.7%).…”

Section: Discussionsupporting

confidence: 92%

“…It had a 0.497 Youden index, a sensitivity of 0.547, and a specificity of 0.950. Also, SuPAR demonstrated an AUC of 0.92 (95% CI:0.56-0.95) as a predictor for CKD stage G3b-5 and 0.74 (95% CI:0.53-0.93) as a marker for DN class IV, according to Lupuș oru et al (19) .…”

Section: Discussionmentioning

confidence: 93%

“…The group I demonstrated significantly higher ACEI or ARBS use (54.3% vs. 22.9%, P = 0.007) and retinopathy (88.6% vs. 37.1%, P <0.001) than group II. Lupuș oru et al (19) looked into research involving 75 cases with DM and DKD, of which 28 developed DN that was confirmed by biopsy. It was noticed that 68% of patients received therapy with either ACEI or ARBs.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Serum suPAR and Urinary Nephrin as Novel Sensitive and Specific Markers for Diabetic Nephropathy in Patients with Type 2 DM

Elhammady,

ELShafie,

El Fallah

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: The most frequent reason of end-stage kidney disease (ESKD) is diabetic nephropathy (DN), highlighting the need of early detection, treatment, and prevention. Objective: To assess the sensitivity and specificity of serum (soluble urokinase-type plasminogen activator receptor (suPAR) and urinary nephrin in cases with type 2 diabetes mellitus (T2DM) with and without nephropathy. Methods: This prospective study was conducted on 70 patients of T2DM and 15 healthy control group of age and sex matched persons. All patients and control group were subjected to pelviabdominal U/S, laboratory investigations (CBC, ESR, liver and kidney function test, fasting and 2 hours post prandial blood sugar, urine analysis, (urine albumin creatinine ratio (UACR), nephrin, and serum suPAR levels). Results: ROC analysis was done for suPAR to predict DN. It showed a significant AUC of 0.869, with a 95% CI ranging from 0.785 -0.953 (P < 0.001). The best cutoff was > 82.3, at which sensitivity and specificity were 97.1% and 68.6%, respectively. ROC analysis was done for urinary nephrin to predict DN. It showed a significant AUC of 0.760, with a 95% CI ranging from 0.642 -0.877 (P < 0.001). The best cutoff was > 10.8, at which sensitivity and specificity were 80% and 68.6%, respectively. Conclusions: In T2DM patients, serum suPAR and urinary nephrin were more specific and sensitive markers than microalbuminuria in early detection of DN.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum suPAR and Urinary Nephrin as Novel Sensitive and Specific Markers for Diabetic Nephropathy in Patients with Type 2 DM

Elhammady,

ELShafie,

El Fallah

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…For example, DN is a highly prevalent and serious diabetic complication. It is expected that by 2045, there will be around 783 million people suffering from diabetes worldwide, and half of the patients will be combined with diabetic nephropathy (Lupusoru et al, 2021; Sun, Saeedi, et al, 2021). Therefore, it is urgent to explore new therapeutic options for DN.…”

Section: Discussionmentioning

confidence: 99%

Chrysin improves diabetic nephropathy by regulating the AMPK ‐mediated lipid metabolism in HFD / STZ ‐induced DN mice

Zhou

Tao

et al. 2022

Journal of Food Biochemistry

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is a highly prevalent and severe diabetic complication. It is urgent to explore high efficiency and minor side effects therapy for DN. Chrysin is a natural flavonoid with various biological activities found in honey and propolis, and has considerable potential to improve DN. The study was designed to explore the effects and the specific underlying mechanism of chrysin for DN in high‐fat‐diet (HFD) and streptozotocin (STZ) induced DN mice. Firstly, the study revealed that chrysin effectively improved obesity, insulin resistance (IR), renal function, and pathological injury in DN mice. Secondly, the study found that chrysin improved the key indices and markers of lipid accumulation, oxidative stress, and inflammation which are closely related to the development or progression of DN. Moreover, chrysin markedly modulated lipid metabolism by regulating Adenosine 5′ monophosphate‐activated protein kinase (AMPK) and essential downstream proteins. Furthermore, AMPK inhibitor (Dorsomorphin) intervention partially suppressed the positive effects of chrysin on all testing indicators, indicating that activated AMPK is crucial for chrysin action on DN. The present study demonstrated that chrysin may improve DN by regulating lipid metabolism, and activated AMPK plays a critical role in the regulation of chrysin. Practical applications The study verified the positive effects of chrysin on obesity, insulin resistance, kidney injury, renal function, lipid accumulation, inflammation, and oxidative stress, which are closely related to the development or progression of diabetic nephropathy (DN). Moreover, we explored that chrysin improves DN by regulating AMPK‐mediated lipid metabolism. Furthermore, the AMPK inhibitor was used to confirm that activated AMPK plays a critical role in the effects of chrysin. These results could offer a full explanation and a potential option for adjuvant therapy of DN diabetes with chrysin.

show abstract

“…Serum levels of soluble urokinase-type plasminogen activator receptor (suPAR) have also been investigated as a potential biomarker in IgA nephropathy. suPAR is a marker of immune activation and inflammation and has been shown to predict the risk of disease progression in several renal diseases, including IgA nephropathy (9,10).…”

Section: Introductionmentioning

confidence: 99%

Biomarkers in IgA nephropathy; an update to recent data

et al. 2023

View full text Add to dashboard Cite

Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.

show abstract

Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy

Cited by 9 publications

References 38 publications

Serum suPAR and Urinary Nephrin as Novel Sensitive and Specific Markers for Diabetic Nephropathy in Patients with Type 2 DM

Serum suPAR and Urinary Nephrin as Novel Sensitive and Specific Markers for Diabetic Nephropathy in Patients with Type 2 DM

Chrysin improves diabetic nephropathy by regulating the AMPK ‐mediated lipid metabolism in HFD / STZ ‐induced DN mice

Biomarkers in IgA nephropathy; an update to recent data

Contact Info

Product

Resources

About